Skip to main content
SpringerLink
Log in

Prostanoids for Pulmonary Arterial Hypertension

  • Review Article
  • Published:
American Journal of Respiratory Medicine

Abstract

Pulmonary arterial hypertension (PAH) is a severe condition that markedly reduces exercise capacity and survival in the affected patient population. PAH includes primary pulmonary hypertension (PPH) and pulmonary hypertension associated with collagen vascular diseases, congenital systemic-to-pulmonary shunts, portal hypertension and HIV infection. All these conditions share virtually identical obstructive pathologic changes of the pulmonary microcirculation and probably similar pathobiologic processes. The pathophysiology is characterized by a progressive increase in pulmonary vascular resistance, leading to right ventricular failure and death. Prostacyclin is an endogenous substance that is produced by vascular endothelial cells and induces vasodilatation, inhibition of platelet activity, and antiproliferative effects. A dysregulation of prostacyclin metabolic pathways has been shown in patients with PAH and this represents the rationale for the exogenous therapeutic administration of this substance.

The clinical use of prostacyclin in patients with PAH has been made possible by the synthesis of stable analogs that possess different pharmacokinetic properties but share similar pharmacodynamic effects. Experience in humans has been initially collected with epoprostenol, which is a synthetic salt of prostacyclin. Epoprostenol has a short half-life in the circulation and requires continuous administration by the intravenous route by means of infusion pumps and permanent tunnelized catheters. In addition, epoprostenol is unstable at room temperature, and the complex delivery system required is associated with several adverse effects and potentially serious complications. For these reasons, alternatives to intravenous epoprostenol have been sought and this has led to the development of analogs that can be administered subcutaneously (treprostinil), orally (beraprost sodium) or by inhalation (iloprost).

Three unblinded clinical trials and several uncontrolled trials have shown that treatment with epoprostenol improved symptoms and exercise capacity in New York Heart Association (NYHA) class III and IV PAH patients and also survival in patients with PPH. Subcutaneous treprostinil improved symptoms, exercise, hemodynamics and clinical events in the largest clinical trial ever performed in PAH, but local infusion site reactions limited efficacy in a proportion of patients. Oral beraprost sodium improved exercise capacity only in patients with PPH and is the only prostacyclin analog that has also been tested in NYHA class II patients. Inhaled iloprost has improved symptoms, exercise capacity and clinical events in patients with PAH and inoperable chronic thromboembolic pulmonary hypertension. The favorable effects of prostanoids observed in all studies coupled with different profiles of adverse events and tolerability for each prostacyclin analog allow the unique opportunity to select the most appropriate compound for the individual patient with PAH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Nomenclature Committee. Nomenclature and Classification of Pulmonary Hypertension. In: Rich S. Primary pulmonary hypertension: executive summary from the World Symposium — Primary Pulmonary Hypertension; 1998: 25–27. 1998, World Health Organization. http://www.who.int/ncd/cvd/pph.html

    Google Scholar 

  2. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111–7

    PubMed  CAS  Google Scholar 

  3. Galie N, Manes A, Uguccioni L, et al. Primary pulmonary hypertension: insights into pathogenesis from epidemiology. Chest 1998; 114: 184S–94S

    PubMed  CAS  Google Scholar 

  4. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40: 453–9

    CAS  Google Scholar 

  5. Brickner ME, Hillis LD, Lange RA. Congenital heart disease in adults: second of two parts [published erratum appears in N Engl J Med 2000 Mar 30; 342 (13): 988]. N Engl J Med 2000; 342: 334–42

    PubMed  CAS  Google Scholar 

  6. Herve P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998; 11: 1153–66

    PubMed  CAS  Google Scholar 

  7. Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension. Circulation 1994; 89: 2722–7

    PubMed  CAS  Google Scholar 

  8. Brenot F, Herve P, Petitpretz P, et al. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993; 70: 537–41

    PubMed  CAS  Google Scholar 

  9. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343–9

    PubMed  Google Scholar 

  10. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487–92

    PubMed  CAS  Google Scholar 

  11. Hopkins WE, Ochoa LL, Richardson GW, et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15: 100–5

    PubMed  CAS  Google Scholar 

  12. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome: factors relating to deterioration and death. Eur Heart J 1998; 19: 1845–55

    PubMed  CAS  Google Scholar 

  13. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80: 1198–206

    PubMed  CAS  Google Scholar 

  14. Brij S, Peacock AJ. Pulmonary hypertension: its assessment and treatment. Thorax 1999; 54Suppl. 2: S28–32

    PubMed  Google Scholar 

  15. Smith ME, Holcroft JW, Demling RH. Prostaglandin E1 and prostacyclin infusion decrease thromboxane production in endotoxin-induced lung injury. J Surg Res 1982; 32: 283–8

    PubMed  CAS  Google Scholar 

  16. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70–5

    PubMed  CAS  Google Scholar 

  17. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214–21

    PubMed  CAS  Google Scholar 

  18. Yuan JX, Aldinger AM, Juhaszova M, et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998; 98: 1400–6

    PubMed  CAS  Google Scholar 

  19. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: 1628–31

    PubMed  CAS  Google Scholar 

  20. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96: 2782–4

    PubMed  CAS  Google Scholar 

  21. Moser KM, Fedullo PF, Finkbeiner WE, et al. Do patients with primary pulmonary hypertension develop extensive central thrombi? Circulation 1995; 91: 741–5

    PubMed  CAS  Google Scholar 

  22. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249–54

    PubMed  CAS  Google Scholar 

  23. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108: 1141–50

    PubMed  CAS  Google Scholar 

  24. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26: 81–4

    PubMed  CAS  Google Scholar 

  25. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (Gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737–44

    PubMed  CAS  Google Scholar 

  26. Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000; 37: 741–5

    PubMed  CAS  Google Scholar 

  27. Humbert M, Deng Z, Simonneau G, et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002; 20: 518–23

    PubMed  CAS  Google Scholar 

  28. Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 325–34

    PubMed  CAS  Google Scholar 

  29. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol 1995; 75: 3A–10A

    PubMed  CAS  Google Scholar 

  30. Nakagawa O, Tanaka I, Usui T, et al. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation 1994; 90: 1643–7

    PubMed  CAS  Google Scholar 

  31. Klings ES, Farber HW. Epoprostenol for pulmonary hypertension in scleroderma [letter]. Ann Intern Med 2000; 133: 158

    PubMed  CAS  Google Scholar 

  32. Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995; 48: 890–6

    PubMed  CAS  Google Scholar 

  33. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197–208

    PubMed  CAS  Google Scholar 

  34. Gryglewski RJ. Interactions between endothelial mediators. Pharmacol Toxicol 1995; 77: 1–9

    PubMed  CAS  Google Scholar 

  35. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70–5

    PubMed  CAS  Google Scholar 

  36. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925–32

    PubMed  CAS  Google Scholar 

  37. Badesch DB, Orton EC, Zapp LM, et al. Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension. Am J Respir Cell Mol Biol 1989; 1: 489–98

    PubMed  CAS  Google Scholar 

  38. Geraci MW, Gao B, Shepherd DC, et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999; 103: 1509–15

    PubMed  CAS  Google Scholar 

  39. Watkins WD, Peterson MB, Crone RK, et al. Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension [letter]. Lancet 1980; I: 1083

    Google Scholar 

  40. Rubin LJ, Groves BM, Reeves JT, et al. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982; 66: 334–8

    PubMed  CAS  Google Scholar 

  41. Galie N, Ussia G, Passarelli P, et al. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995; 75: 55A–62A

    PubMed  CAS  Google Scholar 

  42. Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993; 70: 366–70

    PubMed  CAS  Google Scholar 

  43. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296–302

    PubMed  CAS  Google Scholar 

  44. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273–7

    PubMed  CAS  Google Scholar 

  45. Fishman AP. Pulmonary hypertension: beyond vasodilator therapy. N Engl J Med 1998; 338: 321–2

    PubMed  CAS  Google Scholar 

  46. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96: 2782–4

    PubMed  CAS  Google Scholar 

  47. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80: 1198–206

    PubMed  CAS  Google Scholar 

  48. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732–9

    PubMed  CAS  Google Scholar 

  49. Langleben D, Barst RJ, Badesch D, et al. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation 1999; 99: 3266–71

    PubMed  CAS  Google Scholar 

  50. Prins BA, Hu RM, Nazario B, et al. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 1994; 269: 11938–44

    PubMed  CAS  Google Scholar 

  51. Montalescot G, Drobinski G, Meurin P, et al. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. Am J Cardiol 1998; 82: 749–55

    PubMed  CAS  Google Scholar 

  52. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1184–7

    PubMed  CAS  Google Scholar 

  53. Wax D, Garofano R, Barst RJ. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest 1999; 116: 914–20

    PubMed  CAS  Google Scholar 

  54. Castelain V, Chemla D, Lecarpentier Y, et al. Pressure flow response of the pulmonary circulation after six weeks prostacyclin in primary pulmonary hypertension [abstract]. Am J Respir Crit Care Med 2000; 161: A459

    Google Scholar 

  55. Galie N. Do we need controlled clinical trials in pulmonary arterial hypertension? Eur Respir J 2001; 17: 1–3

    PubMed  CAS  Google Scholar 

  56. Higenbottam T, Wheeldon D, Wells F, et al. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984; I: 1046–7

    Google Scholar 

  57. Jones DK, Higenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). Br Heart J 1987; 57: 270–8

    PubMed  CAS  Google Scholar 

  58. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990; 112: 485–91

    PubMed  CAS  Google Scholar 

  59. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409–15

    PubMed  CAS  Google Scholar 

  60. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800–4

    PubMed  Google Scholar 

  61. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496–502

    PubMed  CAS  Google Scholar 

  62. Olschewski H, Simonneau G, Galie H, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322–9

    PubMed  CAS  Google Scholar 

  63. Barst RJ, McGoon M, McLaughlin VV, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. In press

  64. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296–302

    PubMed  CAS  Google Scholar 

  65. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132: 425–34

    PubMed  CAS  Google Scholar 

  66. Hinderliter AL, Willis PW, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation 1997; 95: 1479–86

    PubMed  CAS  Google Scholar 

  67. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30: 343–9

    PubMed  CAS  Google Scholar 

  68. Higenbottam T, Butt AY, McMahon A, et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80: 151–5

    PubMed  CAS  Google Scholar 

  69. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780–8

    PubMed  CAS  Google Scholar 

  70. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477–82

    PubMed  CAS  Google Scholar 

  71. Cremona G, Higenbottam T. Role of prostacyclin in the treatment of primary pulmonary hypertension. Am J Cardiol 1995; 75: 67A–71A

    PubMed  CAS  Google Scholar 

  72. McLaughlin VV, Meyer PM, Rich S. Prostacyclin improves one year survival in advanced primary pulmonary hypertension regardless of severity [abstract]. J Resp Crit Care Med 2000; 161: 460

    Google Scholar 

  73. Conte JV, Gaine SP, Orens JB, et al. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation. J Heart Lung Transplant 1998; 17: 679–85

    PubMed  CAS  Google Scholar 

  74. Jamieson SW, Trulock EP, Yacoub M. Transplantation for pulmonary hypertension. In: Rich, S. Primary pulmonary hypertension: executive summary from the World Symposium — Primary Pulmonary Hypertension; 1998: 20–21. 2000, World Health Organization, http://www.who.int/ncd/cvd/pph.html

    Google Scholar 

  75. McLaughlin VV, Meyer PM, Rich S. Prognosis of patients with primary pulmonary hypertension following one year of prostacyclin therapy [abstract]. J Resp Crit Care Med 2000; 161: 459

    Google Scholar 

  76. Channick R, Badesch DB, Tapson VF, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant 2001; 20: 262–3

    PubMed  Google Scholar 

  77. Rubin LJ, Badesch DB, Barst RJ, et al, Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346(12): 896–903

    PubMed  CAS  Google Scholar 

  78. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002; 121: 1860–8

    PubMed  CAS  Google Scholar 

  79. Robbins IM, Christman BW, Newman JH, et al. A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Chest 1998; 114: 1269–75

    PubMed  CAS  Google Scholar 

  80. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1184–7

    PubMed  CAS  Google Scholar 

  81. Robbins IM, Cuiper LL, Stein CM, et al. Angiotensin II mediates systemic rebound hypertension after cessation of prostacyclin infusion in sheep. J Appl Physiol 1998; 85: 731–7

    PubMed  CAS  Google Scholar 

  82. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197–208

    PubMed  CAS  Google Scholar 

  83. Robbins IM, Gaine SP, Schilz R, et al. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000; 117: 14–8

    PubMed  CAS  Google Scholar 

  84. McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999; 130: 740–3

    PubMed  CAS  Google Scholar 

  85. Humbert M, Sanchez O, Fartoukh M, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999; 13: 1351–6

    PubMed  CAS  Google Scholar 

  86. Horn EM, Barst RJ, Poon M. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000; 118: 1229–30

    PubMed  CAS  Google Scholar 

  87. Kuhn KP, Byrne DW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003; 167(4): 580–586

    PubMed  Google Scholar 

  88. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858–65

    PubMed  CAS  Google Scholar 

  89. Kuo PC, Johnson LB, Plotkin JS, et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63: 604–6

    PubMed  CAS  Google Scholar 

  90. Bakst AE, Gaine SP, Rubin LJ. Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher’s disease. Chest 1999; 116: 1127–9

    PubMed  CAS  Google Scholar 

  91. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000; 162: 1846–50

    PubMed  CAS  Google Scholar 

  92. Higenbottam T, Butt AY, McMahon A, et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80: 151–5

    PubMed  CAS  Google Scholar 

  93. Palmer SM, Robinson LJ, Wang A, et al. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998; 113: 237–40

    PubMed  CAS  Google Scholar 

  94. Humbert M, Maitre S, Capron F, et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 1998; 157: 1681–5

    PubMed  CAS  Google Scholar 

  95. Okumura H, Nagaya N, Kyotani S, et al. Effects of continuous IV prostacyclin in a patient with pulmonary veno-occlusive disease. Chest 2002; 122: 1096–8

    PubMed  Google Scholar 

  96. Archer SL, Mike D, Crow J, et al. A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest 1996; 109: 750–5

    PubMed  CAS  Google Scholar 

  97. Patterson JH, Adams Jr KF, Gheorghiade M, et al. Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure. Am J Cardiol 1995; 75: 26A–33A

    PubMed  CAS  Google Scholar 

  98. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003; 41(2): 293–9

    PubMed  CAS  Google Scholar 

  99. Vachiery JL, Hill N, Zwicke D, et al. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002; 121: 1561–5

    PubMed  CAS  Google Scholar 

  100. Toda N. Beraprost sodium. Cardio Drug Rev 1998; (6): 222–238

    Google Scholar 

  101. Miyata M, Ueno Y, Sekine H, et al. Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension. J Cardiovasc Pharmacol 1996; 27: 20–6

    PubMed  CAS  Google Scholar 

  102. Ueno Y, Okazaki S, Isogaya M, et al. Positive inotropic and chronotropic effects of beraprost sodium, a stable analogue of prostacyclin, in isolated guinea pig myocardium. Gen Pharmacol 1996; 27: 101–3

    PubMed  CAS  Google Scholar 

  103. Lievre M, Morand S, Besse B, et al. Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 2000; 102: 426–31

    PubMed  CAS  Google Scholar 

  104. Vayssairat M. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. J Rheumatol 1999; 26: 2173–8

    PubMed  CAS  Google Scholar 

  105. Saji T, Ozawa Y, Ishikita T, et al. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996; 78: 244–7

    PubMed  CAS  Google Scholar 

  106. Okano Y, Yoshioka T, Shimouchi A, et al. Orally active prostacyclin analogue in primary pulmonary hypertension [letter]. Lancet 1997; 349: 1365

    PubMed  CAS  Google Scholar 

  107. Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1188–92

    PubMed  CAS  Google Scholar 

  108. Higenbottam TW, Butt AY, Dinh-Xaun AT, et al. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 1998; 79: 175–9

    PubMed  CAS  Google Scholar 

  109. Higenbottam T, Butt AY, McMahon A, et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80: 151–5

    PubMed  CAS  Google Scholar 

  110. Mok MY, Tse HF, Lau CS. Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost. Lupus 1999; 8: 328–31

    PubMed  CAS  Google Scholar 

  111. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124: 820–4

    PubMed  CAS  Google Scholar 

  112. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000; 35: 176–82

    PubMed  CAS  Google Scholar 

  113. Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. German PPH Study Group. Ann Intern Med 2000; 132: 435–43

    PubMed  CAS  Google Scholar 

  114. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342: 1866–70

    PubMed  CAS  Google Scholar 

  115. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160: 600–7

    PubMed  CAS  Google Scholar 

  116. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension [letter]. N Engl J Med 2000; 343: 1342

    PubMed  CAS  Google Scholar 

  117. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84: E4

    PubMed  CAS  Google Scholar 

  118. Ghofrani A, Wiedermann R, Schermuly R, et al. Long-term effectiveness of additional oral sildenafil for improvement of patients with severe pulmonary arterial hypertension treated with inhalative iloprost therapy [abstract]. Am J Respir Crit Care Med 2002; 165: A411

    Google Scholar 

Download references

Acknowledgements

No funding was provided for the preparation of this manuscript. The authors have been involved in the recent new prostanoids trials (trepostinil, beraprost, iloprost) in different positions including investigator, steering and safety committee member.

Author information

Authors and Affiliations

  1. Istituto di Cardiologia, Università di Bologna, via Massarenti, 9, 40138, Bologna, Italy

    Nazzareno Galiè, Alessandra Manes & Angelo Branzi

Authors
  1. Nazzareno Galiè
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandra Manes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angelo Branzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nazzareno Galiè.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galiè, N., Manes, A. & Branzi, A. Prostanoids for Pulmonary Arterial Hypertension. Am J Respir Med 2, 123–137 (2003). https://doi.org/10.1007/BF03256644

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03256644

Keywords

Search

Navigation